Weiss Ratings Reaffirms Sell (D+) Rating for USANA Health Sciences (NYSE:USNA)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D+)" rating for USANA Health Sciences (NYSE:USNA), with the consensus rating for the stock currently at "Reduce" and an average target price of $36.00.
• USANA's stock closed at $20.63, remaining flat, and has a one-year trading range with a low of $18.69 and a high of $41.83.
• Insider selling has been noted, with Director Gilbert A. Fuller selling 1,058 shares, and institutional investors collectively hold 54.25% of the stock.

USANA Health Sciences (NYSE:USNA - Get Free Report)'s stock had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings in a report released on Friday,Weiss Ratings reports.

A number of other research firms have also recently issued reports on USNA. Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a research note on Saturday, October 11th. Zacks Research downgraded shares of USANA Health Sciences from a "hold" rating to a "strong sell" rating in a research report on Tuesday. Two analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and an average target price of $36.00.

USANA Health Sciences Stock Performance

Shares of USNA stock remained flat at $20.63 on Friday. 77,343 shares of the stock traded hands, compared to its average volume of 175,322. USANA Health Sciences has a one year low of $18.69 and a one year high of $41.83. The company has a fifty day simple moving average of $28.06 and a two-hundred day simple moving average of $28.92. The firm has a market cap of $376.91 million, a price-to-earnings ratio of 23.45, a P/E/G ratio of 1.02 and a beta of 0.61.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. USANA Health Sciences had a return on equity of 6.96% and a net margin of 1.86%.The firm had revenue of $200.22 million for the quarter. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. Research analysts expect that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,058 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $29.10, for a total transaction of $30,787.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider David Mulham Mulham sold 3,515 shares of the stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the sale, the insider owned 9,260 shares of the company's stock, valued at approximately $280,207.60. This represents a 27.51% decrease in their position. The disclosure for this sale can be found here. 0.63% of the stock is owned by insiders.

Institutional Investors Weigh In On USANA Health Sciences

Hedge funds have recently bought and sold shares of the company. Pzena Investment Management LLC grew its holdings in USANA Health Sciences by 9.4% during the second quarter. Pzena Investment Management LLC now owns 1,198,260 shares of the company's stock worth $36,583,000 after purchasing an additional 103,074 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of USANA Health Sciences by 202.3% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 97,537 shares of the company's stock worth $2,978,000 after acquiring an additional 65,268 shares during the period. Jacobs Levy Equity Management Inc. increased its holdings in shares of USANA Health Sciences by 46.2% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 188,511 shares of the company's stock worth $5,084,000 after acquiring an additional 59,535 shares during the last quarter. Ameriprise Financial Inc. raised its stake in USANA Health Sciences by 64.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 150,090 shares of the company's stock valued at $4,582,000 after acquiring an additional 58,921 shares during the period. Finally, Exchange Traded Concepts LLC lifted its holdings in USANA Health Sciences by 497.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 47,204 shares of the company's stock valued at $1,300,000 after purchasing an additional 39,297 shares during the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.